Prilosec lawsuits are being investigated over kidney disease, heart attacks and other complications that might re associated with use of the popular heart burn medication.
Bernstein Liebhard is offering fee, no-obligation legal reviews on behalf of patients who may have been harmed by Prilosec. To learn more about filing a Prilosec lawsuit, please call (888) 994-5118.
Prilosec is a prescription Proton Pump Inhibitor (PPI) manufactured by AstraZeneca. The company also sells an over-the-counter version of the heartburn drug, Prilosec 24HR. When prescription Prilosec was launched in 1988, it was the first of the PPI class to come to market.
While PPIs are extremely popular medications, they are not without risk. In recent years, the U.S. Food & Drug Administration (FDA) has updated the labeling of prescription PPIs, including Prilosec, to note a number of serious side effects, including:
Recently, some research has suggested that Prilosec and other PPIs might also increase a person’s risk for kidney disease and heart attack.
In January 2016, a team of researchers from Johns Hopkins University published a study in JAMA: Internal Medicine that suggested the use of PPIs could increase the risk of Chronic Kidney Disease (CKD) by as much as 50%. The team followed 10,482 people for an average of 13.9 years, comparing those who used PPIs to those who did not, or to those who used alternative medications called H2 blockers (Tagamet, Zantac, and Pepcid). While the findings do not prove that drugs like Prilosec cause kidney disease, the report’s authors contend that the subject warrants further study.
Chronic Kidney Disease is a condition that can lead to kidney failure, dialysis and even transplantation. PPIs can cause magnesium levels to decline in the body, which may lead to kidney damage. The drugs can also cause bouts of nephritis, an acute inflammation of the kidneys.
In 2015, a study published in PLOS One suggested that PPIs were associated with a 1.16-fold increased risk for heart attack. That study looked at data contained in 16 million medical documents for 2.9 million people. H2 blockers were not found to increase the chances of a heart attack. The analysis also documented a twofold increase in risk for cardiovascular mortality.
“Our observation that PPI usage is associated with harm in the general population — including the young and those taking no antiplatelet agent — suggests that PPIs may promote risk via an unknown mechanism that does not directly involve platelet aggregation. Accordingly, our recent molecular, cellular, physiological, and in vivo data demonstrating that PPIs inhibit DDAH [dimethylargininase] activity may explain how PPIs promote cardiovascular risk, and do so even in individuals not taking clopidogrel. DDAH, an enzyme necessary for cardiovascular health, metabolizes ADMA, an endogenous and competitive inhibitor of nitric oxide synthase,” the study authors wrote.
Legal help is available to individuals who were diagnosed with kidney disease or who had a heart attack while taking Prilosec. To learn more, please call (888) 994-5118.